Clinical Trial

Phase 2 Study of Fingolimod in Lung Cancers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for efficacy analysis where fingolimod 0.5 mg will be taken orally once daily.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-05-16; most recent amendment 2026-03-25.
Status change: Not Yet Recruiting → Recruiting 2025-05-21
Trial Details
NCT Number NCT06424067
Lead Sponsor Medical University of South Carolina
Conditions Non Small Cell Lung Cancer, Small-cell Lung Cancer
Enrollment 38 participants
Start Date 2025-05-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-30